Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HK2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
HK2 siRNA is a generic experimental research reagent consisting of a small interfering RNA (siRNA) designed to silence the gene encoding hexokinase 2 (HK2). Hexokinase 2 is a key rate-limiting enzyme that catalyzes the first step of glycolysis, converting glucose to glucose-6-phosphate. It is highly upregulated in many cancer types and inflammatory conditions, driving the 'Warburg effect' (aerobic glycolysis). HK2 siRNA is widely used in preclinical research to knock down HK2 expression in cell and animal models, allowing researchers to investigate the therapeutic potential of targeting glycolysis in diseases such as glioblastoma, non-small-cell lung cancer, triple-negative breast cancer, clear cell renal cell carcinoma, rheumatoid arthritis, and infectious diseases.
- Other names
- HK2 small interfering RNAHK-2 small interfering RNAHK 2 small interfering RNAhexokinase 2 siRNAhexokinase2 siRNAhexokinase-2 siRNAsi-HK2si-HK-2si-HK 2siHK2siHK-2siHK 2
02
Targets
HK2 (Hexokinase Type II)
Beyond the preview
Go deeper on HK2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HK2 siRNA.